Dietary Fat, Plasma Lipids, and Other CHD Risk Factors

Cardiovascular Diseases Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00005532
• Other study ID #: 5065
• Secondary ID: R01HL054727
• Status: Completed
• Phase: N/A
• First received: May 25, 2000
• Last updated: January 6, 2016
• Start date: May 1996
• Est. completion date: August 2005

Study information

• Verified date: January 2016
• Source: Tufts University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

To assess the extent to which consumption of different sources of hydrogenated fat relative to unhydrogenated oil or butter alters plasma lipoprotein concentrations and measures of lipid metabolism.

Description:

BACKGROUND:

Although the consumption of trans-fatty acids or hydrogenated fat has consistently been shown to elevate concentrations of total and LDL cholesterol, the effects on HDL-c and Lp(a) are inconsistent, especially when the fats were consumed at moderate levels. In addition, little is known about the mechanisms by which trans-fatty acids increase total and LDL cholesterol levels or how they may alter the atherogenecity of lipoprotein subfractions. The study interventions employ commonly used hydrogenated fats with a wide range of trans-fatty acid levels (1.5-9.8 percent). The impact will be assessed within the guidelines currently recommended for individuals with moderately elevated plasma levels for which dietary modification is often the first approach to treatment. The results of the study may lead to improved public health recommendations concerning trans-fatty acid and hydrogenated fat intake.

DESIGN NARRATIVE:

Forty subjects (20 male, 20 female) ages 50 or older, with LDL cholesterol concentrations greater than 130 mg/dl were fed each of five diets for eight week periods. The baseline diet consisted of 36 percent of energy as fat (15 percent saturated, 15 percent monosaturated, 6 percent polyunsaturated) and 160 mg cholesterol/1000 kcal. The experimental diets contained 30 percent energy as fat, 2/3 of which was derived from each of the following: 1) unhydrogenated liquid soybean oil, 2) soybean oil margarine in tub form, 3) commercial shortening, and 4) butter in a randomized double blind, cross-over design. With the exception of the experimental fat, all other foods in the reduced fat diets were identical.

The study assessed the impact of consuming diets enriched in hydrogenated and other fats on a) plasma lipids and lipoprotein concentrations, b) apolipoproteins A-1 and B and Lp(a) concentrations, c) parameters related to HDL cholesterol [particle size, composition, subfraction distribution (HDL2 and HDL3, and HDL with and without A-II)], d) susceptibility of LDL to oxidation, e) activities of lecithin cholesterol acyltransferase (LCAT) and cholesterol ester transfer protein, and f) rates of endogenous cholesterol synthesis.

The study was renewed in FY 2000 is to assess the impact of newer approaches to dietary modification with the intent of reducing the risk of developing cardiovascular disease. The specific aims of the study are as follow: 1) to assess the impact of substituting two classes of fats specifically formulated to substitute for hydrogenated fats (i.e., trans-free margarines and genetically modified/selectively bred oils) on serum lipid levels (total, VLDL, LDL, HDL, HDL2 and HDL3 cholesterol; triglyceride; apo A-l and B; Lp[a]), immune function, and prostaglandin levels, and 2) to address unresolved issues related to plant sterols, including the relative efficacy of currently available preparations, impact of the fat and cholesterol content of the diet, and effect of dosing frequency on serum lipids, endogenous cholesterol synthesis, cholesterol absorption, and fat soluble vitamin levels. Study subjects are older (50-75 y) hypercholesterolemic female and male subjects (LDL cholesterol 130-160 mg/dl). Each 5-week diet phase will be scheduled in randomized order; all food and drink will be provided. In Part 1, Study 1, subjects will consume each of 3 diets (30 percent fat [2/3 experimental fat], 80 mg cholesterol/1000 kcal) with the following experimental fats: conventional soft margarine; trans-free margarine (interesterified palm kernel + liquid oil); trans-free margarine (fully hydrogenated soybean oil + liquid oil). In Part 1, Study 2, subjects will consume each of 6 diets (as above) with the following experimental fats: hydrogenated soybean (shortening), high oleic sunflower, high oleic soybean, high oleic canola, low saturated soybean and low linolenic soybean oils. In Part 2, Study 1, subjects will consume each of 4 diets (38 percent fat [15 percent SFA, 14 percent MUFA, 6 percent PUFA], 200 mg cholesterol/1000 kcal), baseline and the following: sitostanol ester; sitostenol ester, and genetically modified high sterol oil. In Part 2, Study 2, subjects will consume each of 4 plant sterol enriched diets, high fat (as above) with high (200 mg) or low (80 mg) cholesterol/1000 kcal, and low fat (20 percent fat [5 percent SFA, 7.5 percent MUFA, 7.5 percent PUFA]) with high or low cholesterol. In Part 2, Study 3, the effect of dosing regime will be assessed using the most efficacious plant sterol as identified in Study 1 and diet as in Study 2 (single bolus or in 3 divided doses).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: August 2005
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A to 100 Years
• Eligibility: No eligibility criteria

Study Design

N/A

Related Conditions & MeSH terms

• Atherosclerosis
• Cardiovascular Diseases
• Coronary Artery Disease
• Coronary Disease
• Heart Diseases

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Tufts University	National Heart, Lung, and Blood Institute (NHLBI)

References & Publications (12)

Gordon LB, Harten IA, Patti ME, Lichtenstein AH. Reduced adiponectin and HDL cholesterol without elevated C-reactive protein: clues to the biology of premature atherosclerosis in Hutchinson-Gilford Progeria Syndrome. J Pediatr. 2005 Mar;146(3):336-41. — View Citation

Han SN, Leka LS, Lichtenstein AH, Ausman LM, Schaefer EJ, Meydani SN. Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J Lipid Res. 2002 Mar;43(3):445-52. — View Citation

Lichtenstein AH, Ausman LM, Jalbert SM, Schaefer EJ. Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med. 1999 Jun 24;340(25):1933-40. Erratum in: N Engl J Med 1999 Sep 9;341(11):856. — View Citation

Lichtenstein AH, Ausman LM, Jalbert SM, Vilella-Bach M, Jauhiainen M, McGladdery S, Erkkilä AT, Ehnholm C, Frohlich J, Schaefer EJ. Efficacy of a Therapeutic Lifestyle Change/Step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects. J Lipid Res. 2002 Feb;43(2):264-73. — View Citation

Lichtenstein AH, Erkkilä AT, Lamarche B, Schwab US, Jalbert SM, Ausman LM. Influence of hydrogenated fat and butter on CVD risk factors: remnant-like particles, glucose and insulin, blood pressure and C-reactive protein. Atherosclerosis. 2003 Nov;171(1):97-107. — View Citation

Lichtenstein AH, Jauhiainen M, McGladdery S, Ausman LM, Jalbert SM, Vilella-Bach M, Ehnholm C, Frohlich J, Schaefer EJ. Impact of hydrogenated fat on high density lipoprotein subfractions and metabolism. J Lipid Res. 2001 Apr;42(4):597-604. — View Citation

Matthan NR, Cianflone K, Lichtenstein AH, Ausman LM, Jauhiainen M, Jones PJ. Hydrogenated fat consumption affects acylation-stimulating protein levels and cholesterol esterification rates in moderately hypercholesterolemic women. J Lipid Res. 2001 Nov;42(11):1841-8. — View Citation

Matthan NR, Jalbert SM, Lamon-Fava S, Dolnikowski GG, Welty FK, Barrett HR, Schaefer EJ, Lichtenstein AH. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status. Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1691-6. Epub 2005 Jun 2. — View Citation

Matthan NR, Raeini-Sarjaz M, Lichtenstein AH, Ausman LM, Jones PJ. Deuterium uptake and plasma cholesterol precursor levels correspond as methods for measurement of endogenous cholesterol synthesis in hypercholesterolemic women. Lipids. 2000 Sep;35(9):1037-44. — View Citation

Matthan NR, Welty FK, Barrett PH, Harausz C, Dolnikowski GG, Parks JS, Eckel RH, Schaefer EJ, Lichtenstein AH. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women. Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1092-7. Epub 2004 Apr 15. — View Citation

Mauger JF, Lichtenstein AH, Ausman LM, Jalbert SM, Jauhiainen M, Ehnholm C, Lamarche B. Effect of different forms of dietary hydrogenated fats on LDL particle size. Am J Clin Nutr. 2003 Sep;78(3):370-5. — View Citation

Schwab US, Ausman LM, Vogel S, Li Z, Lammi-Keefe CJ, Goldin BR, Ordovas JM, Schaefer EJ, Lichtenstein AH. Dietary cholesterol increases the susceptibility of low density lipoprotein to oxidative modification. Atherosclerosis. 2000 Mar;149(1):83-90. — View Citation

* Note: There are 12 references in all — Click here to view all references